Articles by Eric Langer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Eric Langer

Eric Langer


is president and managing partner of BioPlan Associates.

Articles
Geographic Proximity Not a Factor in CMO Selection
September 29, 2014

Annual outsourcing study identifies the markets best poised to profit from the internationalization of the outsourcing.

Targeting Different Off-Shore Destinations
September 2, 2014

Annual study shows geographic proximity not a factor in CMO selection.

Study CMO Technical Expertise is Not Enough
September 1, 2014

Sponsors are demanding high levels of professionalism, performance, and effectiveness in managerial areas to accompany CMOs?' technical expertise.

Relationship-building at Top of Mind for Clients
August 2, 2014

Annual study shows CMO technical expertise is not enough.

Cost Is No Longer the Driving Force for Outsourcing
June 29, 2014

With budgets growing, clients see CMOs' costs as less crucial and consider other factors.

Outsourcing No Longer Just for Cost-Cutting
June 2, 2014

With budgets growing, clients see CMOs' costs as less crucial.

Outsourcing Remains Strong In Traditional Areas
May 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Biopharma Outsourcing Activities Update
April 2, 2014

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Top 10 Outsourcing Trends in Biopharmaceutical Manufacturing
February 28, 2014

In biopharmaceutical manufacturing, outsourcing and off-shoring have migrated into much more high-value areas.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here